Not yet recruitingPhase 1NCT06926478
Subconjunctival Humira for Boston Keratoprosthesis
Studying Bullous pemphigoid
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Massachusetts Eye and Ear Infirmary
- Principal Investigator
- Thomas Dohlman, MDMassachusetts Eye and Ear
- Intervention
- Adalimumab Injection(drug)
- Enrollment
- 8 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2026 – 2028
Study locations (1)
- Massachusetts Eye and Ear, Boston, Massachusetts, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06926478 on ClinicalTrials.govOther trials for Bullous pemphigoid
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06291350Peridontal and Intestinal Microbiota in Patients With Gingival Scarring PemphigoidCentre Hospitalier Universitaire de Nice
- RECRUITINGNANCT06479018Deciphering IL-17-dependant Inflammatory Response in Bullous PemphigoidCHU de Reims
- RECRUITINGNCT04198740Proteomic and Metabolomic Lacrimal Fingerprint in Diverse Pathologies of the Ocular SurfaceCentre hospitalier de l'Université de Montréal (CHUM)
- RECRUITINGPHASE3NCT03295383Randomized Clinical Trial Comparing the Safety and Efficacy of Rituximab Versus Oral Cyclophosphamide in Severe Forms of Mucous Membrane PemphigoidUniversity Hospital, Rouen